Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iSpecimen (ISPC) Gains from Sales and Divestitures (2024 - 2025)

iSpecimen (ISPC) has 2 years of Gains from Sales and Divestitures data on record, last reported at $382.0 in Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures fell 78.08% year-over-year to $382.0; the TTM value through Sep 2025 reached $382.0, down 78.08%, while the annual FY2024 figure was $1800.0, N/A changed from the prior year.
  • Gains from Sales and Divestitures reached $382.0 in Q3 2025 per ISPC's latest filing, up from $338.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1800.0 in Q4 2024 and bottomed at $152.0 in Q1 2025.